Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Praxis Precision Medicines (PRAX) granted inducement restricted stock unit awards covering 11,535 shares of common stock to sixty-six new non-executive employees on September 1, 2026.
Rhea-AI Summary
Praxis Precision Medicines (PRAX) granted inducement restricted stock unit awards covering 11,535 shares of common stock to sixty-six new non-executive employees on September 1, 2026. These awards were issued under the company’s 2024 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
The 2024 Inducement Plan is used solely for equity awards to individuals who were not previously employed by Praxis, or after a bona fide break in service, as an inducement to join the company. The restricted stock units will vest in four equal annual installments, subject to each employee’s continued employment on the applicable vesting dates.
Positive
- None.
Negative
- None.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Aug 06 | Earnings report | Positive | +15.9% | Second-quarter results included regulatory progress and cash runway extending into 2028. |
| Aug 04 | Inducement grants | Neutral | +3.0% | RSU awards covered 7,318 shares for 29 new non-executive employees. |
| Jul 30 | Earnings scheduling | Neutral | +0.0% | The company scheduled second-quarter results and its corporate update for August 6. |
| Jul 07 | Partnership agreement | Positive | +3.3% | Praxis and Remagine Labs announced a transdermal ulixacaltamide development collaboration. |
| Jul 02 | Inducement grants | Neutral | -1.6% | RSUs covered 951 shares for five new non-executive employees. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
The two prior inducement-grant notices produced mixed reactions of 2.95% and -1.58%.
Key Terms
restricted stock units financial
inducement plan financial
nasdaq listing rule 5635(c)(4) regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced that on September 1, 2026, the Compensation Committee of Praxis’ Board of Directors granted restricted stock unit awards covering an aggregate of 11,535 shares of its common stock to sixty-six new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the 2024 Inducement Plan). The restricted stock unit awards were granted as inducements material to the employees’ entering into employment with Praxis in accordance with Nasdaq Listing Rule 5635(c)(4).
The 2024 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Praxis, or following a bona fide period of non-employment, as an inducement material to such individuals’ entering into employment with Praxis, pursuant to Nasdaq Listing Rule 5635(c)(4).
The restricted stock units will vest in four equal annual installments, subject to the employee’s continued employment with Praxis on each vesting date.
About Praxis
Praxis Precision Medicines is a fully integrated, leading CNS precision neuroscience biopharmaceutical company, translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across movement disorders and epilepsy, with four late-stage product candidates. For more information, please visit www.praxismedicines.com and follow us on Facebook, LinkedIn and Twitter/X.
Contacts: Investor Contact: Praxis Precision Medicines investors@praxismedicines.com 857-702-9452 Media Contact: Dan Ferry LifeSci Advisors Daniel@lifesciadvisors.com 617-430-7576